ENTITY
Takeda Pharmaceutical

Takeda Pharmaceutical (4502 JP)

214
Analysis
Health CareJapan
Takeda Pharmaceutical Co Ltd focuses on the Research & Development, Manufacturing, Sales and Marketing and Import/Export of Pharmaceutical Drugs. The Company focuses on the following core therapeutic areas: Cardiovascular & Metabolic, Oncology, Central Nervous System, Respiratory & Immunology, General Medicine (Gastrointestinal & Genitourinary) and Vaccine.
more
Refresh
09 Nov 2023 17:22

Takeda: Guidance Lowered Due to Setbacks in Clinical Trials but Pipeline Development Continues

As we have highlighted, Takeda continues to make good progress with its development pipeline where the company has received FDA approval for...

Share
28 Jul 2023 01:23

Takeda: Earnings Beat Driven by Key Drugs and Dengue Vaccine Seeing Positive Momentum

Takeda's 1QFY24 earnings beat consensus driven by growth & launch products. Newly launched dengue vaccine has started generating revenues with new...

Share
13 Jul 2023 00:56

Takeda Pharmaceuticals: Does It Have A Sustainable Competitive Advantage? – Key Drivers

Takeda delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus. Takeda also achieved strong financial...

Logo
130 Views
Share
12 Jul 2023 18:59

Takeda: The Impact of Voluntary Withdrawal of Dengue Vaccine Application in the US Seems Minimal

Takeda has voluntarily withdrawn US BLA application for dengue vaccine citing issues over data collection. Efficacy and safety profiles of the...

Share
19 Jun 2023 18:32

Takeda: Clinical Development of HUTCHMED’s Fruquintinib Progressing Well

Fruquintinib has demonstrated positive results in a Phase III study while it has also been validated and accepted for regulatory review (MAA) by...

Share
x